Most Liquid NASDAQ Biotechnology Companies
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Cash And Equivalents
| Cash And Equivalents | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | GRAL | GRAIL, LLC | 0.13 | 9.49 | 1.21 | ||
| 2 | IRON | Disc Medicine | (0.16) | 2.17 | (0.34) | ||
| 3 | SLRN | ACELYRIN, INC Common | (0.03) | 6.66 | (0.21) | ||
| 4 | AVBP | ArriVent BioPharma, Common | (0.19) | 2.96 | (0.58) | ||
| 5 | NGNE | Neurogene | (0.16) | 4.84 | (0.76) | ||
| 6 | APGE | Apogee Therapeutics, Common | (0.04) | 4.41 | (0.18) | ||
| 7 | LENZ | LENZ Therapeutics | (0.07) | 3.45 | (0.26) | ||
| 8 | GMAB | Genmab AS | (0.03) | 2.79 | (0.09) | ||
| 9 | AMGN | Amgen Inc | 0.18 | 1.53 | 0.28 | ||
| 10 | VRTX | Vertex Pharmaceuticals | 0.25 | 1.50 | 0.37 | ||
| 11 | MRNA | Moderna | (0.03) | 5.33 | (0.16) | ||
| 12 | INCY | Incyte | (0.07) | 2.21 | (0.16) | ||
| 13 | ILMN | Illumina | (0.25) | 2.68 | (0.68) | ||
| 14 | EXEL | Exelixis | 0.08 | 2.42 | 0.20 | ||
| 15 | NVAX | Novavax | (0.02) | 4.74 | (0.08) | ||
| 16 | DNLI | Denali Therapeutics | (0.13) | 4.57 | (0.58) | ||
| 17 | TEM | Tempus AI, Class | 0.14 | 8.30 | 1.17 | ||
| 18 | FTRE | Fortrea Holdings | (0.28) | 4.34 | (1.20) | ||
| 19 | OABI | OmniAb Inc | (0.12) | 4.33 | (0.54) | ||
| 20 | SNY | Sanofi ADR | 0.18 | 1.35 | 0.25 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes. Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).